pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
NOVARTIS · news · pharmadog
← back to NOVARTIS
News mentioning NOVARTIS
235
stories
4d
Platinum-based chemotherapy in childhood causes mutations that age the liver
stat
5d
Why two promising heart drugs flopped and what’s next
stat
5d
STAT+: The gifts from pharma companies that keep on giving
stat
5d
STAT+: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more
stat
5d
STAT+: Cancer medicines remain in short supply across the U.S., survey finds
stat
5d
Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
fiercebiotech
5d
August biopharma layoffs impact just over 500, down 90% year over year
biospace
6d
STAT+: Pharmalittle: We’re reading about an AstraZeneca COPD win, the FDA filling key jobs, and more
stat
6d
Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision
biospace
6d
Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease
biospace
6d
BMS clinches pivotal win for myeloma CAR T in ‘key derisking event’
biospace
6d
Beyond China: Five other overseas destinations for biopharma dollars
biospace
7d
STAT+: FDA warns an API supplier about residue on walls, a corroded product line, and open-toed sandals
stat
7d
Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’
biospace
7d
STAT+: Oura files to goes public, reported $1.2B in earnings
stat
7d
Sandoz unveils plan for biosimilar expansion and new $300M factory in Slovenia
endpoints
7d
STAT+: FDA approves AstraZeneca breast cancer drug
stat
7d
STAT+: Pharmalittle: We’re reading about another Novartis trial failure, a Novo Nordisk setback, and more
stat
7d
Novartis RNA drug falls short in rare muscle disease study
biopharma dive
7d
AstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancer
biospace
7d
Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
biospace
7d
Novartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons
biospace
7d
STAT+: Inhibrx claims first win for long-sought immunotherapy target
stat
7d
STAT+: Roivant lung disease drug hits mid-stage study goals
stat
7d
Updated: Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drug
endpoints
7d
STAT+: Neuromuscular drug from Novartis fails in key study, adding to pressure on company
stat
7d
AI will only revolutionize drug discovery and development if we play to its strengths
biospace
7d
Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
fiercebiotech
7d
Recon: FDA approves AZ’s breast cancer drug over negative adcomm vote; Novartis sees setbacks for drugs targeting cholesterol, m...
raps
8d
Novartis' Phase 3 pelacarsen study miss raises the stakes for Amgen, Lilly
endpoints
← prev
page 2 of 8
next →
